Curatis valuation report: "A stable and exciting growth story"

Thursday, July 25, 2024 @ 12:00 am

Curatis is a unique risk-balanced company, including a profitable and growing Specialty Distribution business and a Search & Development business with an emerging pipeline of products with peak sales ranging from USD 250-500 mn. Successful development and commercialization would be transformational.

Key catalysts include:

C-PTBE-01 - Apply for orphan & rare pediatric disease designation (H2 2024)
C-PTBE-01 - Scientific advice meeting FDA/EMA (H2 2024)
C-PTBE-01 - Partnering agreement (2025)

Full report

You may also be interested in

Swiss Biotech Report 2024 shows sector performing well in 2023 by continuing to embrace international alliances

Record revenues of CHF 7.3 billion (USD 8.1 billion) – Capital investments increase by more than 50% to CHF 2 billion – CHF 1.4 billion by public companies, CHF 0.6 billion by private companies – Significant licensing and M&A activity in 2023 – VectivBio, T3, Vertex, Santhera – R&D investments of publicly traded biotech companies have decreased in line with global markets, wherea
April 23, 2024

LimmaTech and Valneva: Partnership for Shigella vaccine

Valneva obtains exclusive worldwide license for LimmaTech’s S4V Shigella vaccine candidate and adds an attractive Phase 2 clinical asset to Valneva’s R&D pipeline LimmaTech to receive upfront payment, is eligible for future milestone and royalty payments, and will collaborate on S4V clinical development through Phase 2
August 1, 2024

Oryl Photonics is awarded the EIC Transition grant with a European consortium

European consortium FASS receives a prestigious EIC Transition grant of € 2.5 M. FASS stands for ‘Fast and Accurate Solubility for Sustainability’ and aims to bring to the market a revolutionary laboratory instrument for the measurement of the solubility of drug molecules. The consortium is led by EU-OPENSCREEN ERIC, a European research infrastructure with central office in Germany. Other me
July 30, 2024

SOTIO enters into agreement with Biocytogen to expand antibody-drug conjugates pipeline

Option and license agreement includes multiple fully human bispecific antibodies generated with Biocytogen’s proprietary RenLite platform Agreement will enable SOTIO to significantly broaden its next-generation ADC portfolio, including multi-specific ADCs Biocytogen will receive an upfront payment and potential development milestone payments totaling up to $325.5 million
July 16, 2024

Asceneuron secures USD 100 million financing to advance therapeutics in neurodegenerative diseases

Financing led by Novo Holdings, including new investment from EQT Life Sciences – LSP Dementia Fund, OrbiMed and SR One with participation from existing investors M Ventures, Sofinnova Partners, GSK Equities Investments Limited and Johnson & Johnson Innovation – JJDC, Inc. Funds will be used to progress lead asset ASN51, an oral small molecule OGA inhibitor, into Phase 2 clinical developme
July 16, 2024

HAYA Therapeutics: Eric Adam becomes Chief Operating Officer

HAYA Therapeutics, SA, a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs (lncRNAs), today announced that Eric Adam, Ph.D. has joined as Chief Operating Officer (COO)
July 15, 2024